The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

Solid Biosciences (SLDB) stock was launched by Truist with a Buy rating based on positive catalysts and attractive valuation.

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against ...

Due in major part to stock-based compensation, legal and patent services, and third-party consulting, G&A expenses increased from $8.9 million to $13.8 million. Viking Therapeutics, Inc. (NASDAQ ...

Also Read: Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside The class action covers investors who purchased Applied ...

These ratings reflect expectations for the relative performance of Celldex Therapeutics compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future ...

William Blair maintains Viking Therapeutics as a top 2025 pick ... or new licensing deals could significantly affect its stock. William Blair remains confident that Viking offers a valuable ...

Cara Therapeutics is entering an all-stock deal to combine with private, clinical-stage biopharmaceutical company Tvardi Therapeutics. Tvardi will merge with a subsidiary of Cara under the terms ...

During the pre-market hours, Cara's stock is climbing 11.35 percent, to $0.27 on the Nasdaq. Cara Therapeutics NewsMORE Related Stocks ...

Also Read: Viking Therapeutics Garners Analyst Support For ... data from competitors or new licensing deals could significantly affect its stock. William Blair remains confident that Viking ...